HDAC Inhibitors and RECK Modulate Endoplasmic Reticulum Stress in Tumor Cells

• Main Authors: Yun Chen, Ya-Hui Tsai, Sheng-Hong Tseng
• Format: Article
• Language: English
• Published: MDPI AG 2017-01-01
• Series: International Journal of Molecular Sciences
• Subjects: histone deacetylase inhibitors; reversion-inducing cysteine-rich protein with Kazal motifs; endoplasmic reticulum stress; cancers
• Online Access: http://www.mdpi.com/1422-0067/18/2/258

In the tumor microenvironment hypoxia and nutrient deprived states can induce endoplasmic reticulum (ER) stress. If ER stress is not relieved, the tumor cells may become apoptotic. Therefore, targeting ER homeostasis is a potential strategy for cancer treatment. Various chemotherapeutic agents including histone deacetylase (HDAC) inhibitors can induce ER stress to cause cell death in cancers. Some HDAC inhibitors can prevent HDAC from binding to the specificity protein 1-binding site of the promoter of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and up-regulate RECK expression. Up-regulation of RECK expression by HDAC inhibitors has been observed in various cancer types. RECK is a tumor and metastasis suppressor gene and is critical for regulating tumor cell invasiveness and metastasis. RECK also modulates ER stress via binding to and sequestering glucose-regulated protein 78 protein, so that the transmembrane sensors, such as protein kinase RNA-like ER kinase are released to activate eukaryotic translational initiation factor 2α phosphorylation and enhance ER stress. Therefore, HDAC inhibitors may directly induce ER stress or indirectly induce this stress by up-regulating RECK in cancer cells.